MorphoSys in-licenses antibody targeting CD19

Monday 28 June 2010

MorphoSys AG has agreed to pay $13 million for rights to an anti-CD19 monoclonal antibody that is scheduled to start a Phase 1 study in cancer patients in the US shortly. It is the company’s first in-licensing deal for a clinical compound.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Germany